Delisting riskPopularity #4,224
Filana Therapeutics (FLNA)
Developing simufilam, an oral small molecule, for TSC-related epilepsy.
$0.9800
After hours−0.05 (−4.85%)
At close$1.03(+39.28%)
In millions of USD, except per-share figures
| In millions | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 31 | 29 | 25 | 45 | 12 | 13 | 11 | 9 | |
| Research & development | 18 | 21 | 14 | 5 | 4 | 4 | 5 | 3 |
| 13 | 9 | 11 | 40 | 8 | 9 | 6 | 6 | |
| General & administrative | 13 | 9 | 11 | 40 | 8 | 0 | 0 | 0 |
| Operating income | −31 | −29 | −25 | −45 | −12 | −14 | −11 | −9 |
| 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Interest income | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Other non-operating income | −3 | 1 | −1 | −1 | −1 | −1 | −1 | 0 |
| Income before tax | −28 | −28 | −23 | −44 | −11 | −13 | −10 | −9 |
| Net income from continuing operations | −28 | −28 | −23 | −44 | −11 | −13 | −10 | −9 |
| Net income | −28 | −28 | −23 | −44 | −11 | −13 | −10 | −9 |
| EPS, basic | −$0.58 | −$0.57 | −$0.48 | −$0.92 | −$0.22 | −$0.26 | −$0.21 | −$0.18 |
| EPS, diluted | −$0.58 | −$0.57 | −$0.48 | −$0.92 | −$0.22 | −$0.26 | −$0.21 | −$0.18 |
| Weighted average shares, basic | 48 | 48 | 48 | 48 | 48 | 48 | 48 | 48 |
| Weighted average shares, diluted | 48 | 4,810 | 48 | 48 | 48 | 48 | 48 | 48 |
| EBITDA | −28 | −30 | −23 | −44 | −11 | −12 | −10 | −9 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −28 | −30 | −23 | −44 | −11 | −13 | −10 | −9 |